Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2635556 | 0.86 | RAB9A (0.59) | RAB9AMAPTHPGDHTTKMT2A | |
| SCHEMBL2636139 | 0.85 | ALDH1A1 (0.63) | RAB9AMAPTHPGDHTTKMT2A | |
| SCHEMBL2636006 | 0.84 | RAB9A (0.64) | RAB9AMAPTHPGDKMT2ANPC1 | |
| SCHEMBL2635891 | 0.83 | MRGPRX4 (0.45) | RAB9AHPGDHTTKMT2ANPC1 | |
| SCHEMBL2636158 | 0.82 | MAPK1 (0.55) | RAB9AHPGDHTTKMT2AALDH1A1 | |
| SCHEMBL2635113 | 0.82 | ANO1 (0.48) | RAB9AHPGDHTTKMT2ANPC1 | |
| SCHEMBL14743792 | 0.82 | KMT2A (0.48) | RAB9AHPGDHTTKMT2ANPC1 | |
| SCHEMBL2635376 | 0.81 | GRM4 (0.47) | RAB9AMAPTHPGDKMT2ANPC1 | |
| SCHEMBL2635529 | 0.81 | ALDH1A1 (0.56) | RAB9AMAPTHTTKMT2ANPC1 | |
| SCHEMBL2635188 | 0.80 | HTT (0.51) | RAB9AMAPTHPGDHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO KGAA | 2012-08-30 | — | — | US | claimed |
| EP-2438037-A1 | GLYCINE B ANTAGONISTS | Merz Pharma GmbH & Co. KGaA (DE) | 2012-04-11 | — | — | EP | claimed |
| WO-2010139481-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-12-09 | — | — | WO | claimed |
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO KGAA | 2012-08-30 | — | — | US | disclosed |
| EP-2438037-A1 | GLYCINE B ANTAGONISTS | Merz Pharma GmbH & Co. KGaA (DE) | 2012-04-11 | — | — | EP | disclosed |
| WO-2010139481-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | GLRB, GRIN2B, GLRA2 | RAB9A 2053/4885MAPT 1202/4885HPGD 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.